Ares Financial Consulting’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding TVTX
Ares Financial Consulting's TVTX Position: Q3 2026 in Review
Ares Financial Consulting held its Travere Therapeutics (TVTX) position steady in Q3 2026 at 49 shares worth $2.88K. The position accounts for ﹤0.01% of the portfolio, ranked #811.
Ares Financial Consulting first reported a position in TVTX in Q2 2026 and has held it in 2 quarters since. 345 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.
- Ares Financial Consulting held 49 shares of Travere Therapeutics worth $2.88K as of Q3 2026.
- Ares Financial Consulting left its Travere Therapeutics share count unchanged in Q3 2026.
- Travere Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #811 holding.
- Ares Financial Consulting first reported a position in Travere Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 345 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.
Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.